Teva Pharmaceutical Industries (TEVA) Other Working Capital Changes (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Other Working Capital Changes for 9 consecutive years, with $19.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Working Capital Changes fell 81.9% year-over-year to $19.0 million; the trailing twelve-month figure through Jun 2026 stood at -$49.0 million (down 181.67% YoY), and the FY2025 full-year result was $81.0 million, down 85.54% from the prior year.
• Other Working Capital Changes advanced to $19.0 million in Q2 2026 per TEVA's latest filing, from -$54.0 million in the prior quarter.
• Across five years, Other Working Capital Changes topped out at $700.0 million in Q1 2025 and bottomed at -$1.9 billion in Q4 2023.
• Historically, Other Working Capital Changes has averaged -$171.2 million across 5 years, with a median of -$220.5 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Other Working Capital Changes slumped 3666.67% in 2022, then surged 5033.33% in 2024.
• Over 5 years, Other Working Capital Changes stood at $26.0 million in 2022, then soared by 65.38% to $43.0 million in 2023, then plunged by 186.05% to -$37.0 million in 2024, then decreased by 10.81% to -$41.0 million in 2025, then jumped by 146.34% to $19.0 million in 2026.
• According to Business Quant data, Other Working Capital Changes over the past three periods registered $19.0 million, -$54.0 million, and -$41.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.